Development of the ESEx index: a tool for predicting risk of recurrent severe COPD exacerbations

被引:0
|
作者
Valera-Novella, Elisa [4 ,5 ]
Bernabeu-Mora, Roberto [1 ,2 ,3 ]
Montilla-Herrador, Joaquina [4 ,5 ]
Escolar-Reina, Pilar [4 ,5 ]
Garcia-Vidal, Jose Antonio [5 ,6 ]
Medina-Mirapeix, Francesc [4 ,5 ]
机构
[1] Hosp Gen Univ Morales Meseguer, Dept Pneumol, Adva Marques Velez S-N, Murcia 30008, Spain
[2] Univ Murcia, Dept Internal Med, Murcia, Spain
[3] Inst Murciano Invest Biosanitaria IMIB, Res Grp Fisioterapia & Discapacidad, Murcia, Spain
[4] Univ Murcia, Dept Phys Therapy, Murcia, Spain
[5] Inst Murciano Invest Biosanitaria Virgen Arrixaca, Res Grp Fisioterapia & Discapacidad, Murcia, Spain
[6] Univ Murcia, Murcia, Spain
关键词
COPD; five-repetition sit-to-stand test (5-STS); hospital admission; recurrent exacerbation; 6-minute-walk test (6MWT); OBSTRUCTIVE PULMONARY-DISEASE; HOSPITALIZATION;
D O I
10.1177/20406223231155115
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background:In chronic obstructive pulmonary disease (COPD), multiple recurrent severe exacerbations that require hospitalization can occur. These events are strongly associated with death and other clinical complications. Objectives:We aimed to develop a prognostic model that could identify patients with COPD that are at risk of multiple recurrent severe exacerbations within 3 years. Design:Prospective cohort. Methods:The derivation cohort comprised patients with stable, moderate-to-severe COPD. Multivariable logistic regression analyses were performed to develop the final model. Based on regression coefficients, a simplified index (ESEx) was established. Both, model and index, were assessed for predictive performance by measuring discrimination and calibration. Results:Over 3 years, 16.4% of patients with COPD experienced at least three severe recurrent exacerbations. The prognostic model showed good discrimination of high-risk patients, based on three characteristics: the number of severe exacerbations in the previous year, performance in the five-repetition sit-to-stand test, and in the 6-minute-walk test. The ESEx index provided good level of discrimination [areas under the receiver operating characteristic curve (AUCs): 0.913]. Conclusions:The ESEx index showed good internal validation for the identification of patients at risk of three recurrent severe COPD exacerbations within 3 years. These tools could be used to identify patients who require early interventions and motivate patients to improve physical performance to prevent recurrent exacerbations.
引用
收藏
页数:11
相关论文
共 34 条
  • [31] Clinical variables predicting the risk of a hospital stay for longer than 7days in patients with severe acute exacerbations of chronic obstructive pulmonary disease: a prospective study
    Crisafulli, Ernesto
    Ielpo, Antonella
    Barbeta, Enric
    Ceccato, Adrian
    Huerta, Arturo
    Gabarrus, Albert
    Soler, Nestor
    Chetta, Alfredo
    Torres, Antoni
    RESPIRATORY RESEARCH, 2018, 19
  • [32] Predicting Risk of Hospital Admission in Patients With Suspected COVID-19 in a Community Setting: Protocol for Development and Validation of a Multivariate Risk Prediction Tool
    Espinosa-Gonzalez, Ana Belen
    Neves, Ana Luisa
    Fiorentino, Francesca
    Prociuk, Denys
    Husain, Laiba
    Ramtale, Sonny Christian
    Mi, Emma
    Mi, Ella
    Macartney, Jack
    Anand, Sneha N.
    Sherlock, Julian
    Saravanakumar, Kavitha
    Mayer, Erik
    de Lusignan, Simon
    Greenhalgh, Trisha
    Delaney, Brendan C.
    JMIR RESEARCH PROTOCOLS, 2021, 10 (05):
  • [33] Smoking index and COPD duration as potential risk factors for development of osteoporosis in patients with non-small cell lung cancer - A retrospective case control study evaluated by CT Hounsfield unit
    Zhou, Yue
    Hu, Yunxiang
    Yan, Xixi
    Zheng, Yueyue
    Liu, Sanmao
    Yao, Hongmei
    HELIYON, 2023, 9 (10)
  • [34] LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study
    Wedzicha, Jadwiga
    Mezzi, Karen
    Ayers, Tim
    Thach, Chau
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48